FIELD: medicine.
SUBSTANCE: receptor S1P agonist is administered, namely the compound 1-{4-[1-(4-cyclohexyl-3-trifluoromethylbenzyloxyimino)ethyl]-2-ethylbenzyl}azetidine-3-carboxylic acid (Compound A), or its salt, or its pharmaceutically acceptable salt, for use in treatment of an autoimmune condition, where the said receptor S1P agonist for the initial treatment period is administered at a dose that is lower than the standard daily dose of the said receptor S1P agonist, and then the dose is increased according to the Fibonacci sequence until reaching the standard daily dose of the said receptor S1P agonist.
EFFECT: use of these inventions enables to reduce significantly or even eliminate the negative chronotropic side effect, namely the sharp decline in heart rate.
2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DOSING MODE OF S1P RECEPTOR MODULATOR | 2010 |
|
RU2776152C2 |
| COURSE OF TREATMENT WITH APPLICATION OF RECEPTOR S1P AGONIST | 2005 |
|
RU2478384C2 |
| IDENTIFICATION OF PATIENTS' REACTION TO ADMINISTRATION OF S1P RECEPTOR MODULATOR | 2013 |
|
RU2785736C2 |
| MODULATORS OF RECEPTOR S1P FOR TREATMENT OF MULTIPLE SCLEROSIS | 2007 |
|
RU2569732C9 |
| SIP RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | 2007 |
|
RU2495664C2 |
| S1P RECEPTOR MODULATORS FOR MULTIPLE SCLEROSIS TREATMENT | 2007 |
|
RU2617502C2 |
| MODE OF DOSING SELECTIVE S1P1 RECEPTOR AGONIST | 2009 |
|
RU2519660C2 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
| APPLICATION OF SPHINGOSINE-1-PHOSPHATE (SIP) RECEPTOR AGONISTS FOR TREATMENT OF DEGENERATIVE BRAIN DISEASES | 2004 |
|
RU2379030C2 |
| S1P MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN | 2015 |
|
RU2715734C2 |
